271 related articles for article (PubMed ID: 38054981)
1. Fibrocyte Participation in Thyroid-Associated Ophthalmopathy Suggests New Approaches to Therapy.
Smith TJ
Ophthalmic Plast Reconstr Surg; 2023 Dec; 39(6S):S9-S18. PubMed ID: 38054981
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic IGF-I receptor inhibition alters fibrocyte immune phenotype in thyroid-associated ophthalmopathy.
Fernando R; Caldera O; Smith TJ
Proc Natl Acad Sci U S A; 2021 Dec; 118(52):. PubMed ID: 34949642
[TBL] [Abstract][Full Text] [Related]
3. Teprotumumab Divergently Alters Fibrocyte Gene Expression: Implications for Thyroid-associated Ophthalmopathy.
Fernando R; Smith TJ
J Clin Endocrinol Metab; 2022 Sep; 107(10):e4037-e4047. PubMed ID: 35809263
[TBL] [Abstract][Full Text] [Related]
4. The insulin-like growth factor-I receptor and its role in thyroid-associated ophthalmopathy.
Smith TJ
Eye (Lond); 2019 Feb; 33(2):200-205. PubMed ID: 30385883
[TBL] [Abstract][Full Text] [Related]
5. Insulin-like Growth Factor-I Receptor and Thyroid-Associated Ophthalmopathy.
Smith TJ; Janssen JAMJL
Endocr Rev; 2019 Feb; 40(1):236-267. PubMed ID: 30215690
[TBL] [Abstract][Full Text] [Related]
6. Lessons Learned from Targeting IGF-I Receptor in Thyroid-Associated Ophthalmopathy.
Janssen JAMJL; Smith TJ
Cells; 2021 Feb; 10(2):. PubMed ID: 33673340
[TBL] [Abstract][Full Text] [Related]
7. Teprotumumab: The Dawn of Therapies in Moderate-to-Severe Thyroid-Associated Ophthalmopathy.
Ding Y; Yang S; Gao H
Horm Metab Res; 2021 Apr; 53(4):211-218. PubMed ID: 33853117
[TBL] [Abstract][Full Text] [Related]
8. Insulin-Like Growth Factor Pathway and the Thyroid.
Smith TJ
Front Endocrinol (Lausanne); 2021; 12():653627. PubMed ID: 34149612
[TBL] [Abstract][Full Text] [Related]
9. IGF1 receptor and thyroid-associated ophthalmopathy.
Mohyi M; Smith TJ
J Mol Endocrinol; 2018 Jul; 61(1):T29-T43. PubMed ID: 29273685
[TBL] [Abstract][Full Text] [Related]
10. 2021 update on thyroid-associated ophthalmopathy.
Neag EJ; Smith TJ
J Endocrinol Invest; 2022 Feb; 45(2):235-259. PubMed ID: 34417736
[TBL] [Abstract][Full Text] [Related]
11. Clinical Management and Therapeutic Strategies for the Thyroid-Associated Ophthalmopathy: Current and Future Perspectives.
Mishra S; Maurya VK; Kumar S; Ankita ; Kaur A; Saxena SK
Curr Eye Res; 2020 Nov; 45(11):1325-1341. PubMed ID: 32567373
[TBL] [Abstract][Full Text] [Related]
12. Insulin-like growth factor-1 enhances the expression of functional TSH receptor in orbital fibroblasts from thyroid-associated ophthalmopathy.
Paik JS; Kim SE; Kim JH; Lee JY; Yang SW; Lee SB
Immunobiology; 2020 Mar; 225(2):151902. PubMed ID: 31899052
[TBL] [Abstract][Full Text] [Related]
13. Increased generation of fibrocytes in thyroid-associated ophthalmopathy.
Douglas RS; Afifiyan NF; Hwang CJ; Chong K; Haider U; Richards P; Gianoukakis AG; Smith TJ
J Clin Endocrinol Metab; 2010 Jan; 95(1):430-8. PubMed ID: 19897675
[TBL] [Abstract][Full Text] [Related]
14. Challenges in Orphan Drug Development: Identification of Effective Therapy for Thyroid-Associated Ophthalmopathy.
Smith TJ
Annu Rev Pharmacol Toxicol; 2019 Jan; 59():129-148. PubMed ID: 30044728
[TBL] [Abstract][Full Text] [Related]
15. Thyrotropin receptor and CD40 mediate interleukin-8 expression in fibrocytes: implications for thyroid-associated ophthalmopathy (an American Ophthalmological Society thesis).
Douglas RS; Mester T; Ginter A; Kim DS
Trans Am Ophthalmol Soc; 2014; 112():26-37. PubMed ID: 25411513
[TBL] [Abstract][Full Text] [Related]
16. Increased expression of TSH receptor by fibrocytes in thyroid-associated ophthalmopathy leads to chemokine production.
Gillespie EF; Papageorgiou KI; Fernando R; Raychaudhuri N; Cockerham KP; Charara LK; Goncalves AC; Zhao SX; Ginter A; Lu Y; Smith TJ; Douglas RS
J Clin Endocrinol Metab; 2012 May; 97(5):E740-6. PubMed ID: 22399514
[TBL] [Abstract][Full Text] [Related]
17. TSHR as a therapeutic target in Graves' disease.
Smith TJ
Expert Opin Ther Targets; 2017 Apr; 21(4):427-432. PubMed ID: 28127991
[TBL] [Abstract][Full Text] [Related]
18. Teprotumumab, an IGF-1R blocking monoclonal antibody inhibits TSH and IGF-1 action in fibrocytes.
Chen H; Mester T; Raychaudhuri N; Kauh CY; Gupta S; Smith TJ; Douglas RS
J Clin Endocrinol Metab; 2014 Sep; 99(9):E1635-40. PubMed ID: 24878056
[TBL] [Abstract][Full Text] [Related]
19. It Takes Two to Tango: IGF-I and TSH Receptors in Thyroid Eye Disease.
Girnita L; Smith TJ; Janssen JAMJL
J Clin Endocrinol Metab; 2022 Aug; 107(Suppl_1):S1-S12. PubMed ID: 35167695
[TBL] [Abstract][Full Text] [Related]
20. Teprotumumab: a novel therapeutic monoclonal antibody for thyroid-associated ophthalmopathy.
Slentz DH; Nelson CC; Smith TJ
Expert Opin Investig Drugs; 2020 Jul; 29(7):645-649. PubMed ID: 32429706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]